Stereotaxis (NYSE:STXS) today announced the first patients successfully treated in the U.S. with its MAGiC system. MAGiC (magnetic interventional ablation catheter) delivers radiofrequency cardiac ablation to treat heart arrhythmia. The technology received FDA clearance at the start of this year, joining the FDA-cleared MAGiC Sweep robotically … [Read more...] about Stereotaxis reports first US procedures with MAGiC ablation catheter
Stereotaxis
Stereotaxis expects growth in 2026 with manufacturing ramp for new products
Stereotaxis (NYSE:STXS) today reported its fourth-quarter and full-year financial results ahead of expected growth in 2026. The company reported fourth-quarter revenue totaling $8.6 million, marking a 36% increase year-over-year. However, that fell shy of Wall Street expectations for $9.24 million. St. Louis-based Stereotaxis reported total 2025 … [Read more...] about Stereotaxis expects growth in 2026 with manufacturing ramp for new products
Stereotaxis MAGiC cardiac ablation catheter wins FDA approval
Stereotaxis (NYSE:STXS) has won FDA approval for its robotically navigated MAGiC ablation catheter, offering a minimally invasive option for patients who otherwise might not be eligible for cardiac ablation to treat complex and critical heart rhythm disorders. MAGiC is short for "magnetic interventional ablation catheter," an abbreviation … [Read more...] about Stereotaxis MAGiC cardiac ablation catheter wins FDA approval
Stereotaxis reports first commercial robotic HD mapping cases with Magic catheter
Stereotaxis (NYSE:STXS) announced today that it completed the world's first commercial procedures using its Magic Sweep catheter. The MAGiC Sweep catheter is a high-density electrophysiology EP mapping catheter designed for use with Stereotaxis’ Robotic Magnetic Navigation systems. Dr. Raffaele Corbisiero and Dr. Pedram Kazemian performed the … [Read more...] about Stereotaxis reports first commercial robotic HD mapping cases with Magic catheter
Stereotaxis gets FDA green light for robotic electrophysiology mapping catheter
Stereotaxis (NYSE:STXS) announced today that it received FDA 510(k) clearance for its Magic Sweep navigation catheter. The company touts Magic Sweep as the world's first robotically navigated high-density electrophysiology (EP) mapping catheter. High-density mapping enhances cardiac ablation procedures through more efficient, detailed and precise … [Read more...] about Stereotaxis gets FDA green light for robotic electrophysiology mapping catheter
Stereotaxis shares data supporting Magic catheter
Stereotaxis (NYSE:STXS) announced the publication of initial clinical results using its MAGiC robotic magnetic navigation catheter. The results, published in the Journal of Interventional Cardiac Electrophysiology, mark the first peer-reviewed literature supporting the efficacy and safety of MAGiC. MAGiC, a robotically navigated magnetic ablation … [Read more...] about Stereotaxis shares data supporting Magic catheter
Stereotaxis submits pair of catheters for FDA clearance
Stereotaxis today announced it submitted its EMAGIN 5F and MAGiC catheters for FDA clearance. EMAGIN 5F, short for Endovascular Magnetic Intervention, is a 5-French diameter catheter that navigates tortuous venous and arterial vasculature. Stereotaxis designed it to enable efficient and safe navigation to access difficult-to-reach vascular … [Read more...] about Stereotaxis submits pair of catheters for FDA clearance
Stereotaxis Magic ablation catheter is now CE mark approved
Stereotaxis (NYSE:STXS) said today that it has secured CE mark approval for its Magic robotically-navigated magnetic ablation catheter. The St. Louis–based robotic surgery company submitted Magic for both CE mark and FDA approval nearly a year ago; it still awaits an FDA nod in the U.S. Magic performs cardiac ablation procedures to treat … [Read more...] about Stereotaxis Magic ablation catheter is now CE mark approved
Stereotaxis wins approval in China for magnetic ablation catheter
Stereotaxis (NYSE:STXS) announced today that its Magbot magnetic navigation ablation catheter received regulatory approval in China. This nod comes just weeks after the company won approval from China’s National Medical Products Administration for the Genesis robotic magnetic navigation (RNM) system. St. Louis, Missouri-based Stereotaxis aims to … [Read more...] about Stereotaxis wins approval in China for magnetic ablation catheter
Stereotaxis to acquire Access Point Technologies and its EP catheters
Stereotaxis (NYSE: STXS) is purchasing a Minneapolis-based electrophysiology (EP) catheter maker to further enhance its minimally invasive endovascular surgical robotics technology. St. Louis–based Stereotaxis did not disclose how much it is paying for Access Point Technologies in its after-hours news release. The transaction, paid with … [Read more...] about Stereotaxis to acquire Access Point Technologies and its EP catheters





